Literature DB >> 27631412

[Involvement of mucous membranes in autoimmune bullous diseases].

C Günther1.   

Abstract

Autoimmune bullous diseases are characterized by intraepidermal or subepidermal autoantibody deposition that leads to blisters and secondary erosion. Mucous membranes are frequently affected in pemphigus vulgaris and always involved in cicatricial and mucosal pemphigoid. Mucosal lesions are detected less frequently in patients with bullous pemphigoid or epidermolysis bullosa acquisita. The diagnosis of autoimmune bullous disorders is based on determination of the subtype of autoantibodies bound in the skin and the clinical picture. Treatment is based on immunosuppression related to the type of disease and severity of the mucosal symptoms. Ocular involvement in mucosal pemphigoid and pemphigus vulgaris requires systemic treatment.

Entities:  

Keywords:  Autoantibodies; Immunosuppression; Mucosal pemphigoid; Pemphigus vulgaris; Systemic therapy

Mesh:

Substances:

Year:  2016        PMID: 27631412     DOI: 10.1007/s00105-016-3871-6

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  31 in total

1.  Topical tacrolimus treatment for cicatricial pemphigoid.

Authors:  Claudia Günther; Gottfried Wozel; Michael Meurer; Christiane Pfeiffer
Journal:  J Am Acad Dermatol       Date:  2004-02       Impact factor: 11.527

Review 2.  Autoimmune bullous skin diseases. Part 1: Clinical manifestations.

Authors:  Andrea Kneisel; Michael Hertl
Journal:  J Dtsch Dermatol Ges       Date:  2011-10       Impact factor: 5.584

Review 3.  From anti-p200 pemphigoid to anti-laminin gamma1 pemphigoid.

Authors:  Teruki Dainichi; Hiroshi Koga; Takako Tsuji; Norito Ishii; Bungo Ohyama; Akihiro Ueda; Yohei Natsuaki; Tadashi Karashima; Takekuni Nakama; Shinichiro Yasumoto; Detlef Zillikens; Takashi Hashimoto
Journal:  J Dermatol       Date:  2010-03       Impact factor: 4.005

4.  IgG autoantibodies from a lichen planus pemphigoides patient recognize the NC16A domain of the bullous pemphigoid antigen 180.

Authors:  M Skaria; D Salomon; F Jaunin; A Friedli; J H Saurat; L Borradori
Journal:  Dermatology       Date:  1999       Impact factor: 5.366

Review 5.  Immunoadsorption in dermatology.

Authors:  Enno Schmidt; Detlef Zillikens
Journal:  Arch Dermatol Res       Date:  2010-01-05       Impact factor: 3.017

6.  S2k guideline for the diagnosis of pemphigus vulgaris/foliaceus and bullous pemphigoid.

Authors:  Enno Schmidt; Matthias Goebeler; Michael Hertl; Miklós Sárdy; Cassian Sitaru; Rüdiger Eming; Silke C Hofmann; Nicolas Hunzelmann; Johannes S Kern; Harald Kramer; Hans-Dieter Orzechowski; Christiane Pfeiffer; Volker Schuster; Birte Sporbeck; Michael Sticherling; Margitta Worm; Detlef Zillikens; Alexander Nast
Journal:  J Dtsch Dermatol Ges       Date:  2015-07       Impact factor: 5.584

Review 7.  Pemphigoid diseases.

Authors:  Enno Schmidt; Detlef Zillikens
Journal:  Lancet       Date:  2012-12-11       Impact factor: 79.321

Review 8.  [Lupus erythematosus].

Authors:  C Günther; S Beissert
Journal:  Hautarzt       Date:  2015-08       Impact factor: 0.751

Review 9.  The pathophysiology of bullous pemphigoid.

Authors:  Michael Kasperkiewicz; Detlef Zillikens
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 8.667

10.  Successful therapy of pemphigus vulgaris with immunoadsorption using the TheraSorb adsorber.

Authors:  Claudia Günther; Jörg Laske; Antje Frind; Ulrich Julius; Christiane Pfeiffer
Journal:  J Dtsch Dermatol Ges       Date:  2008-03-06       Impact factor: 5.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.